Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Sumiko, Okubo"'
Autor:
Yutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Christopher Ocampo, Apurvasena Parikh, Sumiko Okubo, Kazuteru Fukasawa, Haruyasu Murakami
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2350-2358 (2021)
ABSTRACT Telisotuzumab vedotin (formerly ABBV‐399) is an antibody‐drug conjugate targeting c‐Met–overexpressing tumor cells, irrespective of MET gene amplification status. Safety, pharmacokinetics, and preliminary efficacy of telisotuzumab ve
Externí odkaz:
https://doaj.org/article/e5c74427df9c4e4a8d535b04fd498301
Autor:
Noboru Asada, Jun Ando, Satoru Takada, Chikashi Yoshida, Kensuke Usuki, Atsushi Shinagawa, Kenichi Ishizawa, Toshihiro Miyamoto, Hiroatsu Iida, Nobuaki Dobashi, Sumiko Okubo, Hideyuki Honda, Tomomi Soshin, Yasuko Nishimura, Atsuko Tsutsui, Harumi Mukai, Kazuhito Yamamoto
Publikováno v:
Japanese Journal of Clinical Oncology.
Background In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::890094c59970f17ec0eba76a109652f7
https://doi.org/10.1093/jjco/hyad027
https://doi.org/10.1093/jjco/hyad027
Autor:
Qi Jiang, Kenichi Ishizawa, Satoru Takada, Wellington Luiz Mendes, Toshihiro Miyamoto, Takahiro Yamauchi, Nobuaki Dobashi, M. Kurokawa, Junya Kuroda, Chikashi Yoshida, Sumiko Okubo, Kensuke Usuki, Itaru Matsumura, Norio Komatsu, Andrew H. Wei, Hideyuki Honda, Norio Asou, Hiroatsu Iida, Satoshi Ichikawa, Yasushi Miyazaki
Publikováno v:
Japanese Journal of Clinical Oncology
Background In a multinational phase 3 trial (VIALE-C), venetoclax plus low-dose cytarabine prolonged overall survival vs placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67d4a9567587c0be208bb469ec19ef71
http://europepmc.org/articles/PMC8405845
http://europepmc.org/articles/PMC8405845
Autor:
Apurvasena Parikh, Noboru Yamamoto, Toshio Shimizu, Sumiko Okubo, Kan Yonemori, Christopher Ocampo, Haruyasu Murakami, Kazuteru Fukasawa, Yutaka Fujiwara, Hirotsugu Kenmotsu
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2350-2358 (2021)
Cancer Medicine
Cancer Medicine
Telisotuzumab vedotin (formerly ABBV‐399) is an antibody‐drug conjugate targeting c‐Met–overexpressing tumor cells, irrespective of MET gene amplification status. Safety, pharmacokinetics, and preliminary efficacy of telisotuzumab vedotin wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d21fe73b1e49b6c6bf99c7032724ff3c
https://doi.org/10.1002/cam4.3815
https://doi.org/10.1002/cam4.3815
Autor:
Yasuhito Terui, Sumiko Okubo, Dai Maruyama, Ilseung Choi, Ahmed Salem, Yasuko Nishimura, Koji Izutsu, Su Young Kim, Koji Kato, Kazuhito Yamamoto, Noriko Fukuhara, Kathryn Humphrey, Takayuki Ishikawa, Natsumi Ogawa
Publikováno v:
International Journal of Hematology. 113:370-380
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have limited treatment options. Venetoclax is a potent BCL-2 inhibitor that induces apoptosis in CLL cells. This open-label, phase 1/2 stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbad769342fd434bace100f977d57967
https://doi.org/10.1007/s12185-020-03024-3
https://doi.org/10.1007/s12185-020-03024-3
Autor:
Hideyuki Honda, Yasuhiro Nakashima, Yasushi Miyazaki, Takahiro Yamauchi, Courtney D. DiNardo, Norio Asou, M. Kurokawa, Ying Zhou, Jalaja Potluri, Jiuhong Zha, Kenichi Ishizawa, Keith W. Pratz, Itaru Matsumura, Ilseung Choi, Atsushi Shinagawa, Sumiko Okubo, Kazuhito Yamamoto, Noboru Asada, Norio Komatsu, Noriko Fukuhara, Kensuke Usuki, Chikashi Yoshida, Toshihiro Miyamoto
Publikováno v:
Japanese journal of clinical oncology. 52(1)
Background The phase 3 VIALE-A trial (NCT02993523) reported that venetoclax-azacitidine significantly prolonged overall survival compared with placebo-azacitidine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e460e2c60cb7c6ed9cf4c8d7c6bd6ca5
https://pubmed.ncbi.nlm.nih.gov/34739075
https://pubmed.ncbi.nlm.nih.gov/34739075
Autor:
Hideyuki Honda, Wan Jen Hong, Sumiko Okubo, Yasuko Nishimura, Ahmed Salem, Noriko Fukuhara, Ilseung Choi, Jalaja Potluri, Takahiro Yamauchi, Shuichi Taniguchi, Kensuke Usuki
Publikováno v:
Japanese journal of clinical oncology. 51(6)
Background Venetoclax plus azacitidine is indicated in the USA for the treatment of newly diagnosed acute myeloid leukaemia in older patients (≥75 years) or those ineligible for induction chemotherapy due to co-morbidities. Methods In this phase 1/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b957777ba323f5fd395b558e61db5ff1
https://pubmed.ncbi.nlm.nih.gov/33712849
https://pubmed.ncbi.nlm.nih.gov/33712849
Autor:
Masashi Takahashi, Keisuke Tomii, Shoji Kudoh, Sumiko Okubo, Noriko Kobayashi, Sotaro Enatsu, Satoshi Noma, Terufumi Kato, Yoichiro Kobashi
Publikováno v:
Japanese Journal of Clinical Oncology. 47:350-356
Background Interstitial lung disease (ILD) is important drug related toxicity because it commonly forced to discontinue the treatment. Methods To characterize the prevalence and patterns of pemetrexed induced ILD, an independent ILD advisory board co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869e7d3be7d256392d3e65472095fa14
https://doi.org/10.1093/jjco/hyx010
https://doi.org/10.1093/jjco/hyx010
Autor:
Silpa Nuthalapati, Hirokazu Tanaka, Su-Peng Yeh, Norio Komatsu, Kota Ono, Sumiko Okubo, Hui-Hua Hsiao, Kotaro Uehara, Hirohiko Shibayama
Publikováno v:
Blood. 136:15-16
Background: Navitoclax (Nav) is a small-molecule inhibitor of several antiapoptotic B-cell lymphoma 2 (BCL2) family proteins, including BCL-xL, BCL2, and BCL-W. Preclinical studies have demonstrated that when administered alone, Nav can effectively i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ac3e8eb66478871f4a7f8cdd8517b36
https://doi.org/10.1182/blood-2020-137068
https://doi.org/10.1182/blood-2020-137068
Autor:
Yutaka Fujiwara, Kazuhiko Nakagawa, Ikuko Yasuda, Hiroaki Akamatsu, Keisuke Kirita, Masayuki Shintani, Shintaro Kanda, Matthew P. Kosloski, Kentaro Tanaka, Shunsuke Teraoka, Hibiki Udagawa, Isamu Okamoto, Sumiko Okubo, Charity D. Scripture, Masayuki Takeda, Tomohide Tamura
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 135
Objectives Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) on small cell lung cancer (SCLC) tumors, is internalized and releases the toxin pyrrolobenzodiazepine to induce cell death. This ope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0d5f6ce727d240e0ddecf492e59fedf
https://pubmed.ncbi.nlm.nih.gov/31446987
https://pubmed.ncbi.nlm.nih.gov/31446987